Can neutrophil-lymphocyte ratio be a useful criterion for neuroleptic malignant syndrome in the absence of leukocytosis?

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: Neuroleptic malignant syndrome (NMS) is a rare but severe side effect of antipsychotic medication. Neutrophil-lymphocyte ratio (NLR) is a simple marker used to measure systemic inflammation. Method: In this case report we explore the relationship of inflammation in the etiology of NMS. In our case involving NMS, although there was no leukocytosis, the NLR was increased up to systemic infection levels. Conclusion: We hypothesized that systemic inflammation may take a role in developing NMS. If so, NLR could be a new marker of NMS that may be able to provide more sensitive results than leukocyte levels.

Cite

CITATION STYLE

APA

Kalelioglu, T., Celikel, G., Balaban, O. D., Karamustafalioglu, N., & Penberthy, J. K. (2021). Can neutrophil-lymphocyte ratio be a useful criterion for neuroleptic malignant syndrome in the absence of leukocytosis? Iranian Journal of Psychiatry, 16(3), 370–373. https://doi.org/10.18502/ijps.v16i3.6264

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free